Treatment of Pyoderma Gangrenosum

Diagnosis and Treatment Approach

The American College of Dermatology recommends avoiding surgical debridement during active pyoderma gangrenosum, as pathergy (trauma-induced lesion worsening) is a defining feature, and surgery will worsen the condition 1
The diagnosis of pyoderma gangrenosum should be confirmed by exclusion, ruling out ecthyma gangrenosum (bacterial vasculitis requiring antibiotics, not immunosuppression), and biopsy from lesion periphery helps exclude infection, malignancy, and vasculitis 1

The European Crohn’s and Colitis Organisation recommends systemic corticosteroids as the established first-line treatment for pyoderma gangrenosum, with the goal of achieving rapid healing 2, 1
For smaller lesions, topical tacrolimus or pimecrolimus can be used as alternatives or adjuncts 1

The Journal of Crohn's and Colitis suggests infliximab 5 mg/kg should be initiated if rapid response to corticosteroids is not achieved, with response rates exceeding 90% for disease duration <12 weeks but dropping below 50% for chronic cases (>3 months) 2, 1
Adalimumab represents an alternative anti-TNF option with demonstrated efficacy 1

Stoma closure may lead to complete resolution of peristomal pyoderma gangrenosum lesions, according to the Journal of Crohn's and Colitis 2, 1
Topical tacrolimus is an alternative when stoma closure is not feasible 2

Recurrence occurs in >25% of cases, often at the same anatomical location as the initial episode, as reported by Praxis Medical Insights 1
Lesions typically heal without sequelae within 4 weeks after treatment discontinuation, according to the Annals of Oncology 3
Frequent clinical follow-up (at least every 2 weeks) is mandatory during active treatment, as recommended by the Annals of Oncology 3